Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials

2017 ◽  
Vol 32 (1) ◽  
pp. 68-72 ◽  
Author(s):  
C. Paul ◽  
L. Guenther ◽  
H. Torii ◽  
H. Sofen ◽  
R. Burge ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document